About Cynaptec
Pharmaceuticals
Cynaptec is a biopharmaceutical company dedicated to developing innovative therapies for neurological and psychiatric disorders Cynaptec’s initial development program is focused on the use of its proprietary Conjugated Psilocin™ compound for treatment of the significant unmet medical needs of patients with Chronic Cluster Headache, with an additional preliminary proof-of-concept to assess potential utility for substance use disorders.
Conjugated Psilocin™ is a novel, patented, oral, stable analog of psilocin, the active metabolite of the prodrug psilocybin, designed to enhance bioavailability and therapeutic efficacy, which has been identified as having therapeutic potential in a variety of neurological conditions.
MORE ABOUT US
In July of 2024, Lobe Sciences underwent a series of changes in ownership, board, and advisory team.
Short biographies and a brief overview for our company leadership can be found above in both the Our Team tab and on the Corporate Profile page.
Altemia®
Medical Food
Altemia, Inc. is focused on the commercialization of treatments to address diseases associated with membranopathy.
Membranopathy is a fatty acid disorder caused by an error in metabolism.
Our initial target is a deficiency associated with Sickle Cell Disease (SCD), the rare orphan disease primarily impacting children and young adults.